|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
平凡之路123 发表于 2019-4-21 07:01 
知道乙克为什么没成功吗，因为华丽家族（收购乙克的公司）的股票没有暴涨。
如果乙克有了风吹草动，华丽家 ...
"知道乙克为什么没成功吗" 你又错了!. YIC已完成3期临床试验（450例患者）研究仍在进行中.不要用股票市场来评估科学.
https://www.tandfonline.com/doi/ ... 660?needAccess=true
Human Vaccines & Immunotherapeutics 12:1, 77--84; January 2016; © 2016 Taylor & Francis Group, LLC
Immuno-potentiating pathway of HBsAg-HBIGimmunogenic complex visualized Hu Liu1,2, Shuang Geng1, Bo Wang1, Bing Wu2, Xiaoping Xie2, Shuang Wang2, Yiwei Zhong1, Xuanyi Wang1,DiQu1,Yumei Wen1, and Bin Wang1,*
1Key Laboratory of Medical Molecular Virology of MOH and MOE; Fudan University Shanghai Medical College; Shanghai, China;
2China State Key Laboratory forAgro-Biotechnology; College of Biological Science; China Agricultural University; Beijing, China
Keywords:cross-presentation, chronic hepatitis B, therapeutic vaccine, dendritic cells, HBsAg-anti-HBs complex
Chronic viral hepatitis B (CHB) is a major global health problem. A therapeutic vaccine for CHB comprised of yeast-derived recombinant HBsAg-anti-HBs immunogenic complexes (YIC) has been developed by us. A series of clinical trials has shown its therapeutic efficacy in decreasing HBV viral load and converting serum HBeAg-positive to anti-HBe-positive status in a subpopulation of CHB patients. Herein, we present a study of the immuno-potentiating mechanisms of YIC revealed by live-cell imaging technology. We studied internalization and dissociation of YIC in cells in vitro, and antigen presentation and T cell stimulation in mice. We found that after YIC was internalized via the Fcg receptors(FcgR) of antigen presenting cells, it was subsequently transferred through early and late endosomal into lysosomal compartments. The dissociation of YIC was mainly observed in the late endosome. Furthermore when YIC were injected into mice, the populations of IFN-g- and TNF-a-producing CD8Cand CD4CT cells were higher in the YIC group than in controls receiving antigen or antibody alone. These observations supplement the known mechanisms of YIC action as a therapeutic vaccine for CHB.
HBsAg-HBIG免疫复合物的免疫增强途径可视化胡柳1,2，双庚1，王波1，吴兵2，谢小平2，王爽2，王义伟1，王玄义1，狄钦1，俞梅文1，王斌1，*
1卫生部和教育部医学分子病毒学重点实验室;复旦大学上海医学院;上海，中国;
2中国农业生物技术国家重点实验室;生物科学学院;中国农业大学;中国北京
关键词：交叉呈递，慢性乙型肝炎，治疗性疫苗，树突状细胞，HBsAg-抗-HBs复合物
慢性病毒性乙型肝炎（CHB）是一个主要的全球健康问题。我们开发了一种用于CHB的治疗性疫苗，其由酵母衍生的重组HBsAg-抗HBs免疫原性复合物（YIC）组成。一系列临床试验显示其在CHB患者亚群中降低HBV病毒载量和将血清HBeAg阳性转化为抗HBe阳性状态的治疗效果。在此，我们提出了通过活细胞成像技术揭示的YIC的免疫增强机制的研究。我们研究了体外细胞中YIC的内化和解离，以及小鼠中的抗原呈递和T细胞刺激。我们发现，在YIC通过抗原呈递细胞的Fcg受体（FcgR）内化后，它随后通过早期和晚期内体转移到溶酶体区室中。 YIC的解离主要在晚期内体中观察到。此外，当YIC注射到小鼠中时，产生IFN-g和TNF-α的CD8C和CD4CT细胞群在YIC组中比在仅接受抗原或抗体的对照中更高。这些观察结果补充了YIC作用的已知机制，作为CHB的治疗性疫苗。 |
|
楼主: 丰华硕实
发表于 2019-4-21 09:26
